Menu Close

NAFDAC alerts consumers to unregistered, harmful energy drink

*Nigeria’s National Agency for Food and Drugs Administration and Control cautions consumers against the recalled G Fuel brand Energy Drinks by T&E Imports and GPAE Trading Corp, containing high levels of caffeine that could cause headaches, insomnia and nervousness

Alexander Davis | ConsumerConnect

In continuation of its consumer protection initiatives, the National Agency for Food and Drugs Administration and Control has notified the public that the recalled G Fuel brand Energy Drinks by T&E Imports and GPAE Trading Corp contains high levels of caffeine.

ConsumerConnect reports  the health regulatory agency stated this in a public alert with No. 034/2023, issued Thursday, November 2, 2023, in Abuja, FCT.

Prof. Mojisola Adeyeye, Director-General of NAFDAC, in the notice, said that the agency was equally notified about the recall of the product by the Netherlands Food and Consumer Product Safety Authority and the Canadian Food Inspection Agency.

Adeyeye said the consumption of products containing high levels of caffeine could cause headaches, insomnia, irritability, and nervousness.

The health regulator equally warned consumers sensitive to caffeine could experience these effects at very low consumption levels.

The Director-General also cautioned pregnant women not to take these products.

The possible health effects of consuming too much caffeine include the risk of miscarriage and a chance of low birth weight, she stated.

NAFDAC disclosed the affected products have no cautionary statement to limit the number of servings per day, adding that these products are sold online.

The product is not registered by NAFDAC, which implored consumers and retailers to refrain from using, selling, serving, or distributing the implicated product.

Adeyeye further noted: “Members of the public are encouraged to report any suspicion of distribution and sale of unwholesome packaged food products to the nearest NAFDAC office.

“NAFDAC could also be reached on 0800-162-3322 or via email: sf.alert@nafdac.gov.ng.

“Healthcare professionals and patients are also encouraged to report adverse events or side effects related to the use of any substandard NAFDAC-regulated product to the nearest NAFDAC office.”

She stated: “NAFDAC could also be reached through the use of the E-reporting platforms available on the NAFDAC Web site: www.nafdac.gov.ng or via the Med-safety application available for download on Android and IOS stores.

“The public could also reach NAFDAC via e-mail at pharmacovigilance@nafdac.gov.ng.”

Kindly Share This Story

 

 

 

 

Kindly share this story